1. Garcia-Carbonero, R., Capdevila, J., Crespo-Herrero, G., Diaz-Perez, J. A., Martinez Del Prado, M. P., Alonso Orduna, V., … Salazar, R. (2010). Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Annals of Oncology : Official Journal of the European Society for Medical Oncology/ESMO, 21(9), 1794–1803. 10.1093/annonc/mdq022
2. Benavent, M., De Miguel, M. J., & Garcia-Carbonero, R. (2012). New targeted agents in gastroenteropancreatic neuroendocrine tumors. Targeted Oncology. doi: 10.1007/s11523-012-0218-9 .
3. Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., … Gwyther, S. G. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. Journal of the National Cancer Institute, 92(3), 205–216.
4. Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., … Verweij, J. (2009). New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). European Journal of Cancer (Oxford, England : 1990), 45(2), 228–247. doi: 10.1016/j.ejca.2008.10.026
5. Rinke, A., Muller, H. H., Schade-Brittinger, C., Klose, K. J., Barth, P., Wied, M., … Group, P. S. (2009). Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 27(28), 4656–4663 10.1200/JCO.2009.22.8510